CAR-T cell therapy has shown great potential in certain lymphoma and leukemia patients. However, resistance to the CAR-T cells in some patients limits the utility of the therapy. In a Sartorius Webinar, Dr. Dr. Adrian Bot, VP and Global Head of Translational Medicine and the Head of Research in Santa Monica at Kite talks about the underlying mechanisms of CAR-T therapy resistance and the development of Axi-cel.
According to the the webinar page on Sartorius, “Using reverse translational deep learning in the context of clinical trials and real-world utilization, he defines actionable factors that contribute to efficacy and toxicity, leading to potential treatment optimization and next generation products with increased clinical performance.”
Sign up for the free webinar and their newsletter by clicking here.
(Source: Sartorius, January 6th, 2021)